ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Epidermal growth factor receptor (EGFR) is implicated in head and neck squamous cell carcinoma (HNSCC) pathogenesis.
• Current anti-EGFR therapies benefit only a subset of HNSCC patients, necessitating novel therapeutic strategies.

Purpose of the Study:

• To investigate novel interactions and signaling pathways involving EGFR in HNSCC.
• To identify potential new therapeutic targets and biomarkers for HNSCC.

Main Methods:

• Unbiased proteomics screening to identify EGFR interacting proteins.
• Utilized structural mutants of EGFR and ANO1 to define interaction domains.
• Assessed the functional and regulatory relationship between ANO1 and EGFR in HNSCC cell lines.

Main Results:

• Identified ANO1 as an interacting partner of EGFR, facilitating EGFR signaling in HNSCC.
• ANO1 and EGFR form a functional complex regulating HNSCC cell proliferation, with reciprocal effects on protein stability and levels.
• Co-inhibition of ANO1 and EGFR demonstrated an additive effect on HNSCC cell proliferation.
• ANO1 overexpression correlated with enhanced sensitivity to Gefitinib, an EGFR inhibitor.

Conclusions:

• ANO1 is a key regulator of EGFR signaling and HNSCC cell proliferation.
• Co-targeting ANO1 and EGFR presents a promising strategy to enhance HNSCC therapy and overcome resistance.
• ANO1 may serve as a predictive biomarker for response to EGFR-targeted therapy in HNSCC.